Many metabolic diseases can be attributed to chronic inflammation. The effect of Coenzyme Q10 (CoQ10, ubiquinone-10) on inflammatory markers in patients with metabolic disease has recently been evaluated. CoQ10 is a compound produced by the body and stored in the cell’s mitochondria. It not only acts as a key cofactor in the mitochondrial electron transport system, it is also a potent antioxidant and modulator of gene expression.
In one recent review, the effects of CoQ10 on inflammation were examined in patients with existing clinical inflammatory markers. Nine trials involving 428 subjects were included in this meta-analysis. The daily dose of CoQ10 varied from 100 to 500 mg, and all control groups received placebo. CoQ10 supplementation was demonstrated to significantly improve the serum level of CoQ10 by 1.17 µg/ml [[MD = 1.17, 95% CI (0.47 to 1.87) μg/ml, I2 = 94%]. It also decreased TNF-α by 0.45 pg/ml [MD = -0.45, 95% CI (-0.67 to -0.24) pg/ml, I2 = 0%].
This review reiterates what previous studies have reported with regard to CoQ10’s positive influence on the inflammatory process. In a separate single-blind, randomized cross over clinical trial, patients with end-stage renal disease (ESRD) demonstrating high oxidative stress received either a placebo or 100mg/day of CoQ10. Results showed that C-reactive protein (CRP) levels, another important inflammatory marker, significantly decreased (P<0.001) (P < 0.001) (95% CI = -20.1 to -10.5) in patients receiving 100 mg/d of CoQ10 versus the patients receiving the placebo.
Finally, in another systematic review and meta-analysis of randomized controlled trials, published in Pharmacological Research, it was demonstrated that CoQ10 had significant lowering effects on CRP, IL-6 and TNF-α.
The main verdict of this recent review was that both the serum level[s] of CoQ10 and the inflammatory markers were significantly improved in [the] CoQ10 supplementation group compared with placebo group in patients with metabolic diseases.